Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Olaparib in Combination With Ceralasertib in Patients With Recurrent Osteosarcoma

NCT04417062 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT04417062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04417062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Olaparib in Combination With Ceralasertib in Patients With Recurrent Osteosarcoma
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 24, 2020
Completion date
December 1, 2026
Enrollment
49 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

osteosarcoma, osteosarcoma recurrent